Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031914 | 1.00 | L3MBTL1 (0.41) | L3MBTL1LMNASMN1; SMN2ATMNAAA | |
| SCHEMBL30030929 | 1.00 | L3MBTL1 (0.41) | L3MBTL1LMNASMN1; SMN2ATMNAAA | |
| SCHEMBL30030874 | 1.00 | L3MBTL1 (0.41) | L3MBTL1LMNASMN1; SMN2ATMNAAA | |
| SCHEMBL30031351 | 0.94 | LMNA (0.42) | L3MBTL1LMNASMN1; SMN2ATMNAAA | |
| SCHEMBL30031073 | 0.83 | L3MBTL1 (0.42) | L3MBTL1LMNASMN1; SMN2ATMKCNA5 | |
| SCHEMBL30030886 | 0.80 | L3MBTL1 (0.41) | L3MBTL1LMNASMN1; SMN2ATMKCNA5 | |
| SCHEMBL30030853 | 0.80 | L3MBTL1 (0.41) | L3MBTL1LMNASMN1; SMN2ATMKCNA5 | |
| SCHEMBL30031158 | 0.78 | CCKBR (0.41) | L3MBTL1LMNASMN1; SMN2ATMNAAA | |
| SCHEMBL30031109 | 0.77 | ATM (0.48) | ATM | |
| SCHEMBL30031757 | 0.76 | ACACB (0.39) | L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12534475-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-27 | — | — | US | disclosed |
| US-12077546-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4324834-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022215754-A1 | BICYCLIC PYRIDINE DERIVATIVE | 住友ファーマ株式会社 | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYP2B6 | L3MBTL1 3912/4885LMNA 4115/4885SMN1; SMN2 1570/4885 |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | L3MBTL1 3221/4885LMNA 3722/4885SMN1; SMN2 2462/4885 |
| US-12077546-B2 | Bicyclic pyridine derivative | CBR1, CBR3, CYB5R3 | L3MBTL1 3221/4885LMNA 3722/4885SMN1; SMN2 2462/4885 |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | L3MBTL1 3221/4885LMNA 3722/4885SMN1; SMN2 2462/4885 |
| US-12534475-B2 | Bicyclic pyridine derivative | CBR1, CYP2B6, CBR3 | L3MBTL1 3101/4885LMNA 4229/4885SMN1; SMN2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.